Sean Brusky
Fortune : 533 000 $ au 30/06/2026
Fortune : 533 000 $ au 30/06/2026
Sean P.
Brusky is currently Chief Business Officer at Prelude Therapeutics, Inc. since 2024.
Former roles include Head-Healthcare Delivery Innovation at Genentech, Inc., Manager-Business & Corporate Development at Vertex Pharmaceuticals, Inc. from 2001 to 2004, and Chief Commercial Officer at Pardes Biosciences, Inc. Education includes undergraduate studies at Brown University and an MBA from Harvard Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/03/2026 | 100 000 ( 0,15% ) | 533 000 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 01/04/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/08/2004 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
| PARDES BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Pardes Biosciences, Inc.
Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral antiviral treatment for COVID-19 | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national